Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP; FORCIDP Trial Investigators. Hughes R, et al. Among authors: genge a. Lancet Neurol. 2018 Aug;17(8):689-698. doi: 10.1016/S1474-4422(18)30202-3. Epub 2018 Jul 9. Lancet Neurol. 2018. PMID: 30001923 Free article. Clinical Trial.
Muscle diseases.
Genge A, Shapira AH, Griggs RC. Genge A, et al. J Clin Neuromuscul Dis. 1999 Dec;1(2):114. doi: 10.1097/00131402-199912000-00015. J Clin Neuromuscul Dis. 1999. PMID: 19078567 No abstract available.
Validation and interpretation of neurological registry data.
Pringsheim T, Lam D, Day L, Genge A, Hogan DB, Shevell M, Fortin CM, Maxwell C, Fiebelkorn G, Barlow K, Kapral MK, Casha S, Mobach T, Johnston M, Jette N, Korngut L. Pringsheim T, et al. Among authors: genge a. Can J Neurol Sci. 2013 Jul;40(4 Suppl 2):S51-3. doi: 10.1017/s0317167100017182. Can J Neurol Sci. 2013. PMID: 23787269 Review. No abstract available.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.
Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupler E, Lou JS, Ensrud E, Tan E, Goldstein JM, Katz J, Dimachkie MM, Barohn RJ, Mozaffar T. Bedlack RS, et al. Among authors: genge a. J Neuropathol Exp Neurol. 2011 Jan;70(1):96-7; author reply 98-100. doi: 10.1097/NEN.0b013e318204782b. J Neuropathol Exp Neurol. 2011. PMID: 21173608 No abstract available.
128 results